R&D nke Sorrento lekwasịrị anya na ịnya ụgbọ ala ọhụrụ na COVID-19, ọgwụgwọ ọrịa kansa, njikwa mgbu zuru oke na ọrịa autoimmune.

Mmemme igodo	Ntu	Mgbochi	Na-adọ 1	Oge Abụọ	Nkeji III/Pivotal	Nkwado FDA
Mmemme COVID-19
COVISTIX™ (nchọpụta nchọpụta) Nnwale Antigen ngwa ngwa 0%* Ikike iji ihe mberede (EUA) na Mexico (COFEPRIS), Brazil (ANVISA), na CE akara na Europe. COVIMARK™ (nchọpụta nchọpụta) Nnwale Antigen ngwa ngwa 0%* Ngwa etinyere na US na Canada maka ikike iji ihe mberede (EUA) VIREX (nchọpụta nchọpụta) N'ụlọ nyocha 60.2%* EUA Enabling Studies in Q3 2022 COVISHIELD™ (ọgwụgwọ) Neutralizing Antibody (IV) n'ime ndị ọrịa na-arịa ọrịa na ndị ọrịa nọ n'ụlọ ọgwụ 20%* FUJOVEE (Abivertinib) COVID-19 siri ike na ndị ọrịa ICU 82%* Ọnwụnwa dị mkpa na-echere mkpochapụ FDA OQORY™ (COVI-MSC) ARDS n'ihi COVID-19 n'ime ndị ọrịa ICU 82%* Ọnwụnwa dị mkpa na Brazil Mpro Ihe mgbochi (ọgwụ ọnụ) Ọrịa mgbochi 40%* Omicron mRNA ogwu Vaccine 20%*
Mmemme igodo	Ntu	Mgbochi	Na-adọ 1	Oge Abụọ	Nkeji III/Pivotal	Nkwado FDA
immunotherapy
FUJOVEE (Abivertinib) NSCLC 82%* FUJOVEE (Abivertinib) B cell Lymphomas 60.2%* FUJOVEE (Abivertinib) Prostate 20%* FUJOVEE (Abivertinib) Lupus 20%* FUJOVEE (Abivertinib) MS 20%* FUJOVEE (Abivertinib) GvHD 20%* PD-L1 (Socazolimab)* SCLC 82%* * Na mmekorita ya na Lee's Pharm na China PD-L1 (STI-3031)** Ọrịa Cervical 82%* ** Na US yana mmekorita ya na ImmuneOncia na Korea CD47 Tumor siri ike 40%* CD38 DAR-T multiple Myeloma 40%* CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, na esophageal 40%* Seprehvec™ oncolytic nje Tumor siri ike; CNS Tumor 40%* Ọnụ ego nke BCMA ADC Tumor Liquid 20%* Bevacizumab-ADNAB™ Ọrịa kansa Endometrial 40%* Na mmekorita ya na Mayo Clinic Bevacizumab-ADNAB™ Ọrịa Ovarian 40%* Na mmekorita ya na Mayo Clinic Rituximab-ADNAB™ B-cell Lymphomas 40%* Na mmekorita ya na Mayo Clinic Sofusa® mgbochi PD-1 Ọrịa T-cell Lymphoma (CTCL), Melanoma 40%*
Mmemme igodo	Ntu	Mgbochi	Na-adọ 1	Oge Abụọ	Nkeji III/Pivotal	Nkwado FDA
Pain
ZTlido® 1.8% Neuralgia Postherpetic - PHN 99.8%* Gloperba® Ọgwụgwọ gout (Oral) 99.8%* SEMEXA (SP-102) Lumbar Radicular/Sciatica mgbu 82%* SP-103 (Sistemụ Topical Lidocaine 5.4%) Nnukwu Mgbu mgbu 60.2%* SP-104 (Naltrexone obere dose gbawara egbu oge) Fibromyalgia 20%* RTX (resiferatoxin) Epidural injection Ihe mgbu na-adịghị agwụ agwụ na ọrịa kansa dị elu 60.3%* Nhọpụta nwa mgbei RTX (resiferatoxin) Ụzọ intra-articular OA Mgbu OA Na-agafeghị agafe ruo Dị Ike 60.2%*
Mmemme igodo	Ntu	Mgbochi	Na-adọ 1	Oge Abụọ	Nkeji III/Pivotal	Nkwado FDA
Nnyefe ọgwụ Lymphatic
Sofusa® mgbochi TNF Autoimmune (RA) 40%* Sofusa® mgbochi PD-1 Ọrịa T-cell Lymphoma (CTCL), Melanoma 40%* Sofusa® mgbochi CTLA-4 Melanoma 40%* Na mmekorita ya na Mayo Clinic

Mmemme COVID-19
Mmemme igodo (Ngosipụta)	adọ
COVISTIX™ (nchọpụta nchọpụta) FDA EUA COVIMARK™ (nchọpụta nchọpụta) FDA EUA VIREX (nchọpụta nchọpụta) PH III COVISHIELD™ (ọgwụgwọ) PH I FUJOVEE (Abivertinib) Ph III OQORY™ (COVI-MSC) Ph III Mpro Ọgwụ mgbochi (ọgwụ nke ọnụ) Ph II Omicron mRNA ogwu Mgbochi

immunotherapy
Mmemme igodo (Ngosipụta)	adọ
FUJOVEE (Abivertinib) Ph III FUJOVEE (Abivertinib) Ph II FUJOVEE (Abivertinib) Mgbochi FUJOVEE (Abivertinib) Mgbochi FUJOVEE (Abivertinib) Mgbochi FUJOVEE (Abivertinib) Mgbochi PD-L1 (Socazolimab)* Ph III PD-L1 (STI-3031)** Ph III CD47 Tumor siri ike Ph I CD38 DAR-T (Otu Myeloma) Ph I CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, na esophageal) Ph I Seprehvec™ oncolytic nje Tumor siri ike (CNS Tumors) PH I Ọnụ ego nke BCMA ADC ( Tumor Liquid) Mgbochi Bevacizumab-ADNAB™ (ọrịa cancer endometrial) Ph I Bevacizumab-ADNAB™ (ọrịa cancer ovarian) Ph I Rituximab-ADNAB™ (B-cell Lymphomas) Ph I Sofusa® mgbochi PD-1 Ọrịa T-cell Lymphoma (CTCL), Melanoma Ph I

Pain
Mmemme igodo (Ngosipụta)	adọ
ZTlido® 1.8% (Postherpetic Neuralgia - PHN) Nkwado FDA Gloperba® 1.8% Ọgwụgwọ gout (Oral) Nkwado FDA SEMEXA (SP-102) Ph III SP-103 (Sistemụ Topical Lidocaine 5.4%) Ph II SP-104 (Naltrexone obere dose gbawara egbu oge) Mgbochi RTX (resiferatoxin) Epidural injection Ph II RTX (resiferatoxin) Ụzọ intra-articular Ph II

Nnyefe Lymphatic
Mmemme igodo (Ngosipụta)	Oge Abụọ
Sofusa® mgbochi TNF (Akụkụ nke onwe RA) Ph I Sofusa® mgbochi PD-1 Ọrịa T-cell Lymphoma (CTCL), Melanoma Ph I Sofusa® mgbochi CTLA-4 (Melanoma) Ph I